Inovexa - Company finances
|
EUR
|
2023
From: 2023-05-29
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 22,752 | 44,704 | 45,264 |
| Profit before tax | 11,625 | 6,557 | 6,597 |
| Net profit | 11,625 | 6,229 | 6,201 |
| Equity | 11,625 | 6,254 | 6,254 |
| Liabilities | 632 | 4,745 | 4,745 |
| Non-current assets | 0 | 6,846 | 6,846 |
| Current assets | 12,257 | 4,153 | 4,153 |
| Total assets | 12,257 | 10,999 | 10,999 |
|
Taxes paid
|
|||
| STI taxes | 3,347 | 9,992 | 9,013 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +96.5% | +1.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 94.8% | 56.6% | 56.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 99.6% | 99.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 51.1% | 13.9% | 13.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 51.1% | 14.7% | 14.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.8 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Inovexa - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-02-01 | 2025-02-28 | 7.95 |
| 2024-05-02 | 2024-05-31 | 5.87 |
| 2024-04-03 | 2024-04-30 | 5.87 |
| 2024-02-01 | 2024-03-31 | 5.87 |
Inovexa - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-18 | 2025-02-18 | 726.08 |
| 2025-02-13 | 2025-02-17 | 1499.08 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Inovexa, MB (code 306328188) is a Small partnership operating in other computer programming activities. In the latest financial year 2025, the company generated EUR 45.3K in revenue and EUR 6.2K in net profit, resulting in a profit margin of 13.7%. Revenue increased by 1.2% year on year, while the two-year comparison shows almost a doubling of turnover versus 2023. The 2023 figures cover a shorter 216-day period, with revenue of EUR 22.8K and net profit of EUR 11.6K, so the year-to-year comparison should be viewed with that in mind. Profitability has remained positive, although net profit in 2024 and 2025 was lower than in 2023. At the end of 2025, total assets stood at EUR 11.0K, equity at EUR 6.3K and liabilities at EUR 4.7K. The balance sheet indicates a moderate leverage position, with a debt-to-equity ratio of 0.76 and an equity ratio of 56.9%. Asset turnover was 4.12x, suggesting efficient use of the asset base in relation to revenue.